Mu-opioid receptor (MOPr) agonists, such as morphine, produce greater antinociception in male compared to female rats. The ventolateral periaqueductal gray (vlPAG) appears to contribute to this sex-difference despite fewer vlPAG output neurons projecting to the rostral ventromedial medulla in male compared to female rats. This greater projection in female rats suggests that non-opioid activation of vlPAG output neurons should produce greater antinociception in female compared to male rats. This hypothesis was tested by comparing the time course and antinociceptive potency of microinjecting MOPr agonists (morphine, DAMGO, fentanyl) and non-opioid compounds (bicuculline, kainic acid) into the vlPAG of female and male rats. Microinjection of morphine or DAMGO produced antinociception that had a slow onset (peak from 15 to 30 min) and long duration (60 min) compared to the antinociception produced following microinjection of fentanyl, bicuculline, or kainic acid (peak effect at 3 min; duration less than 30 min). No sex-differences in the time courses were evident. All five compounds caused a dosedependent antinociception when microinjected into the vlPAG. Antinociceptive potency was significantly greater in male compared to female rats following microinjection of morphine, DAMGO, and bicuculline, but not following microinjection of fentanyl or kainic acid. In no case did activation of the vlPAG produce greater antinocicepiton in female compared to male rats. These findings demonstrate that the vlPAG can produce comparable antinociception in female and male rats, but antinociception produced by inhibition of GABAergic neurons (whether by morphine or the GABA A receptor antagonist bicuculline) produces greater antinociception in males.
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Introduction
Mu-opioid receptor (MOPr) agonists, such as morphine, are commonly used to treat pain. Morphine antinociception tends to be greater in males compared to females in humans and other species [4, 8, 14, 25] . Although the mechanism underlying this sex-difference in antinociception has not been determined, the descending nociceptive modulatory system that includes the ventrolateral periaqueductal gray (vlPAG) appears to contribute [16, 17, 20, 21] . The vlPAG modulates nocieption via a pathway that involves the rostral ventromedial medulla (RVM) and the dorsal horn of the spinal cord [2] . Microinjection of morphine directly into the vlPAG produces antinociception [11, 12, 30] and blockade of MOPr in the vlPAG attenuates antinociception produced by systemic morphine administration [3, 18, 40] .
The finding of greater morphine antinociception in males is surprising given that the vlPAG to RVM projection is much denser in female compared to male rats [21] . However, female rats have lower MOPr expression within the vlPAG than male rats and morphine activation of vlPAG neurons projecting to the RVM is greater in male compared to female rats [3, 19, 23] . These findings indicate that female rats have a much greater descending pathway not activated by MOPr agonists compared to male rats. An interesting question is whether these non-morphine activated projections contribute to nociceptive modulation. If these output neurons contribute to antinociception, then direct activation of vlPAG output neurons should produce greater antinociception in female compared to male rats. This hypothesis was tested by comparing the antinociceptive effects of microinjecting an excitatory amino acid (kainic acid), a GABA A receptor antagonist (bicuculline) and MOPr agonists (morphine, DAMGO, and fentanyl) into the vlPAG of female and male rats.
MOPr agonists and bicuculline produce antinociception by disinhibiting tonically active GABAergic neurons, but MOPr agonists primarily inhibit presynaptic release whereas bicuculline prevents postsynaptic binding [39] . Thus, comparing the effects of morphine and bicuculline will reveal whether sex-differences are mediated by opioid sensitive GABAergic neurons or output neurons (see Fig. 1 
